Vitiligo stability is a vital prerequisite in the management of vitiligo. Vitiligo status based on patient history is an inaccurate tool to evaluate disease stability. Vitiligo disease activity score (VIDA) is considered as an indicator for disease activity. Recently, serum C-X-C motif chemokine ligand 10 (CXCL10) serve as a crucial indicator used for evaluating disease-related activity/stability. Objective: This study aimed to evaluate serum CXCL10 in relation to clinical assessment and VIDA score, to ascertain whether serum CXCL10 could be potential dependable serum marker for vitiligo activity and to define a serum CXCL10 level for activity. Methods: Clinical assessment and VIDA score were performed on one hundred patients diagnosed with the disease of vitiligo included in this cross-sectional research study. We measured the serum level of CXCL10 in vitiligo patients using the enzyme-linked immunosorbent assay (ELISA) method and a serum CXCL10 level for activity was defined. Results: The current study revealed that CXCL10 was significant in relation to clinical assessment and VIDA score. The sensitivity and specificity of measured biomarker was evaluated using the ROC curve. Serum level of CXCL10 more than 102 ng/L, the vitiligo lesion was considered active. Conclusion: Serum CXCL10 could be candidate as a biomarker to evaluate vitiligo activity. There is a positive relationship to disease activity, indicating that CXCL10 may play a significant role in the pathogenesis of vitiligo.

CXCL10; VIDA; activity; vitiligo.